J&J, with adult approval in sight, posts adolescent myasthenia gravis data on $6.5B FcRn blocker

Johnson & Johnson has burnished the evidence for nipocalimab, adding a sliver of data in adolescents with generalized myasthenia gravis (gMG) to the growing case for its near-approval FcRn blocker.